1. KT-621 showed 94% skin and 98% blood STAT6 degradation. 2. Significant Type 2 inflammatory biomarker reductions were observed. 3. Clinical activity yielded 63% mean EASI reduction overall. 4. KT-621 was well-tolerated with no serious adverse events. 5. Ongoing Phase 2b trials are expected to report data by mid-2027.
FAQ
Why Bullish?
The strong clinical results of KT-621 could drive increased investor interest and stock price. Positive outcomes in clinical trials often correlate with stock price appreciation in biotech companies.
How important is it?
The positive data from KT-621 reinforces the company’s position in immunological diseases, potentially attracting more investments and partnerships.
Why Long Term?
The ongoing trials and expected future data releases will influence KYMR's valuation over time, as successful therapies can lead to revenue generation and market presence.
Related Companies
Kymera Therapeutics Announces Promising Results from BroADen Phase 1b Clinical Trial of KT-621
WATERTOWN, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) – Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company focused on advancing oral small molecule degrader medicines, has announced positive findings from its BroADen Phase 1b clinical trial investigating KT-621, a first-in-class oral STAT6 degrader medicine for patients suffering from moderate to severe atopic dermatitis (AD).
Key Trial Findings
In the BroADen study, KT-621 demonstrated impressive efficacy, achieving substantial STAT6 degradation with median reductions of 94% in skin and 98% in blood across the tested doses of 100 mg and 200 mg. These results show a strong translation of findings from healthy volunteers to patients with atopic dermatitis.
- Type 2 Biomarkers Reduction: Significant reductions were observed in disease-relevant biomarkers such as TARC (median reduction of 74%), Eotaxin-3, IL-31, and IgE.
- Clinical Activity: There was a mean reduction of 63% in the Eczema Area and Severity Index (EASI) and a 40% reduction in the peak pruritus numeric rating scale (NRS) across all patients.
- Comorbid Conditions: Patients with asthma experienced a median 56% reduction in FeNO and improved asthma control.
- Well-tolerated Treatment: KT-621 exhibited a favorable safety profile with no serious adverse events reported.
Expert Commentary on KT-621
“The BroADen study results exceeded our highest expectations and provide powerful validation of our STAT6 degrader program,” stated Nello Mainolfi, PhD, Founder, President, and CEO of Kymera Therapeutics. “KT-621 has the potential to be a once-daily oral treatment for Type 2 inflammatory diseases, showing efficacy across all measures we evaluated.”
Jared Gollob, MD, Chief Medical Officer of Kymera Therapeutics, emphasized the significance of the consistency across all endpoints measured, stating, “KT-621 achieved strong results, including robust STAT6 degradation and reductions in core Type 2 inflammation, positioning it as a promising approach for AD and associated comorbidities.”
Ongoing Development and Future Trials
The ongoing BROADEN2 Phase 2b trial for KT-621 in moderate to severe atopic dermatitis is anticipated to deliver data by mid-2027. Additionally, the BREADTH Phase 2b trial in asthma patients is scheduled to start in the first quarter of 2026.
Kymera Therapeutics aims to continue advancing its innovative research and is grateful to the patients and clinical teams whose support has been crucial to the progress made thus far.
Study Design and Methodology
The BroADen Phase 1b trial was an open-label study enrolling 22 patients with moderate to severe atopic dermatitis. Patients were treated with KT-621, with ten receiving 100 mg and twelve receiving 200 mg daily for 28 days, followed by a 14-day follow-up period.
The study's primary objectives included evaluating safety, tolerability, and the ability of KT-621 to achieve significant STAT6 degradation in both blood and skin.
About Kymera Therapeutics (NASDAQ: KYMR)
Kymera Therapeutics is dedicated to developing innovative therapies for autoimmune diseases and cancers through its unique platform of protein degrader medicines. The company aims to bring transformative treatments to patients with unmet medical needs, reinforcing its position as a leader in this exciting area of biopharmaceutical research.